July 20, 2026 02:13 PM GMT Dyne Therapeutics Inc | North America Z-Rostudirsen Granted Priority Review; Incremental Positive as Momentum Builds Key Takeaways Z-rostudirsen launch remains on track for 1Q27 following BLA acceptance and Priority Review. Earlier today, Dyne announced that the FDA accepted for review the Biologics License Application (BLA) for z-rostudirsen (DYNE-251) in DMD patients amenable to exon 51 skipping, granted priority review, and assigned a January 21, 2027 PDUFA target action date ( ...